Therapy for immunologic disease

Preview

“An excellent topic and a very timely review,” said one peer reviewer of Dr Katz's article. Such a comment is not surprising in view of the recent significant advances in the development of new treatment protocols using standard pharmacologic agents for treatment of immunologically mediated diseases, such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, Wegener's granulomatosis, and polymyositis. Until newer agents are developed, alternate-day or short-term high-dose therapy with corticosteroids or chronic low-dose treatment with cytotoxic agents will have to suffice for the treatment of this group of disorders.